GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

116 calculators match

Most used

21
MELD-NaAssesses the severity of chronic liver diseaseChild-Pugh ScoreAssesses the prognosis of chronic liver disease, mainly cirrhosisFIB-4 IndexLiver fibrosis scoring indexAPRIAST to platelet ratio — liver fibrosisMaddrey's DFAlcoholic hepatitis severityGlasgow-BlatchfordUpper GI bleed risk stratificationGAHSGlasgow alcoholic hepatitis scoreMontreal IBDIBD classification — CD & UCMayo ScoreUlcerative colitis activityBISAP ScoreBedside index for severity of pancreatitisCLIF-SOFAOrgan failure scoring in cirrhosisAlcohol ContentStandard drinks & alcohol grams calculatorAARC-ACLFAcute-on-chronic liver failure gradePELD / CR ScorePediatric end-stage liver diseaseHarvey-BradshawCrohn's disease activity indexCTSICT severity index — pancreatitisRockall ScoreGI bleed rebleeding & mortality riskCAGEAlcohol use disorder screening (4 questions)MELD 3.0Updated MELD — sex-inclusive formulaAUDIT ScoreAlcohol use disorders identification testVOCAL-Penn ScorePost-operative mortality risk in cirrhosis surgery

Liver & Cirrhosis

17
ALBI GradeAlbumin-bilirubin liver function grade in HCCUKELD ScoreUK model for end-stage liver diseaseMELD-XIMELD excluding INR — for anticoagulated patientsWest Haven CriteriaHepatic encephalopathy gradingMilan CriteriaLiver transplant eligibility in hepatocellular carcinomaLI-RADS v2018 (CT/MRI)Liver observation category from size, APHE and major featuresBCLC StagingHepatocellular carcinoma stage and treatment allocationSimplified AIH CriteriaSimplified criteria for autoimmune hepatitisRevised Original AIH ScoreIAIHG 1999 comprehensive autoimmune hepatitis scoreSAAGSerum-ascites albumin gradient — cause of ascitesR FactorHepatocellular vs cholestatic pattern in liver injuryCLIF-C ACLFMortality prediction in acute-on-chronic liver failureKing's College CriteriaTransplant criteria in acute liver failureGALAD ScoreHCC detection from gender, age, AFP-L3, AFP and DCPMetroticket 2.0AFP-adjusted up-to-seven for HCC transplant eligibilityRUCAMCausality in drug- and herb-induced liver injuryBaveno VII CriteriacACLD, CSPH and sparing screening endoscopy

Fibrosis & MASLD

8
NAFLD Fibrosis ScoreAdvanced fibrosis probability in MASLD/NAFLDBARD ScoreBMI, AST/ALT ratio, diabetes — MASLD fibrosisFatty Liver IndexPredicts hepatic steatosis from routine labsFibrotic NASH Index (FNI)At-risk NASH probability from AST, HbA1c and HDLNAFLD Activity Score (NAS)Histologic activity grade — steatosis, inflammation, ballooningMEFIB IndexMRE + FIB-4 rule for significant fibrosis (≥F2) in MASLDFAST ScoreFibroScan-AST — at-risk NASH from LSM, CAP and ASTSAFE ScoreSteatosis-Associated Fibrosis Estimator for MASLD in primary care

Pancreas & Biliary

8
Ranson's CriteriaAcute pancreatitis severity at 48 hoursGlasgow-Imrie CriteriaAcute pancreatitis severity — the PANCREAS criteriaHAPSHarmless acute pancreatitis scoreTokyo Guidelines — CholangitisTG18 diagnosis and severity grade for acute cholangitisTokyo Guidelines — CholecystitisTG18 diagnosis and severity grade for acute cholecystitisBiliary Pain (Rome IV)Rome IV — defining biliary-type pain before interventionFunctional Pancreatic SODRome IV — pancreatic sphincter of Oddi disorderRevised Atlanta ClassificationAcute pancreatitis severity — mild, moderately severe, severe

IBD

9
Truelove & Witts CriteriaAcute severe ulcerative colitis — admission decisionUCEISUlcerative colitis endoscopic index of severitySCCAISimple clinical colitis activity index — symptoms onlyCDAICrohn's disease activity index — the trial standardSES-CDEndoscopic severity in Crohn's diseasePUCAIPaediatric ulcerative colitis activity indexTravis (Oxford) CriteriaDay 3 colectomy risk in acute severe ulcerative colitisHo IndexDay 3 steroid failure risk in acute severe ulcerative colitisRutgeerts ScorePostoperative Crohn's recurrence at ileocolonoscopy

GI Bleeding

7
EVendo ScorePredicts oesophageal varices needing treatmentForrest ClassificationPeptic ulcer bleeding — rebleeding risk at endoscopyAIMS65 ScoreUpper GI bleed mortality — five bedside criteriaOakland ScoreSafe-discharge risk for acute lower GI bleedingABC ScoreAge, blood tests, comorbidities — GI bleed mortalitySarin ClassificationEndoscopic classification of gastric varicesEGUS (Gastric Ulcer)Malignancy risk in a gastric ulcer, and who needs repeat endoscopy

Alcohol

2
ABIC ScoreAge, bilirubin, INR, creatinine — alcoholic hepatitisLille ModelSteroid response at day 7 in alcoholic hepatitis

Upper GI

4
Chicago Classification v4.0Oesophageal motility pattern from high-resolution manometryLA Classification (Oesophagitis)Los Angeles grade A–D for erosive oesophagitisPrague C & M CriteriaCircumferential and maximal extent of Barrett's oesophagusEREFS (Eosinophilic Oesophagitis)Endoscopic reference score — oedema, rings, exudates, furrows, stricture

Colorectal

3
Boston Bowel Prep ScaleColonoscopy preparation adequacy by segmentStool Osmotic GapOsmotic vs secretory diarrhoea from stool electrolytesATLAS Score (C. difficile)Predicted response to therapy in Clostridioides difficile infection

Functional GI

37
Bristol Stool ScaleStool form types 1–7 and colonic transitRome IV Criteria for IBSIrritable bowel syndrome diagnosis and subtypeFunctional ConstipationRome IV — two of six items, IBS excludedOpioid-Induced ConstipationRome IV — constipation tied to opioid therapyFunctional DiarrhoeaRome IV — loose stools without predominant painFunctional Bloating / DistensionRome IV — bloating without other bowel disorder criteriaUnspecified Functional Bowel DisorderRome IV — bowel symptoms fitting no other categoryCentrally Mediated Abdominal Pain (CAPS)Rome IV — continuous pain unrelated to gut eventsNarcotic Bowel SyndromeRome IV — opioid-induced hyperalgesia of the gutFaecal Incontinence (Rome IV)Rome IV — the criteria, and why nobody is askedFunctional Anorectal PainLevator ani, unspecified pain and proctalgia fugaxFunctional Defecation DisordersRome IV — dyssynergia and inadequate propulsionInfant RegurgitationRome IV — the happy spitter, and the alarm features that rule it outInfant ColicRome IV — recurrent unexplained crying in a well infant under 5 monthsInfant DyscheziaRome IV — straining before a soft stool, and why not to intervenePaediatric Functional ConstipationRome IV — two of six over one month, with overflow soiling as a criterionToddler's DiarrhoeaRome IV functional diarrhoea of childhood — painless, thriving childPaediatric Cyclic Vomiting SyndromeRome IV — both age bands, with different criteria for eachPaediatric Rumination SyndromeRome IV — infant and child/adolescent criteriaFunctional Nausea & Vomiting (Children)Rome IV — two separate disorders that can be met togetherAerophagiaRome IV — distension that increases through the dayPaediatric Functional DyspepsiaRome IV — four times a month, with PDS and EPS subtypingPaediatric Irritable Bowel SyndromeRome IV — plus the constipation clause clinicians missAbdominal MigraineRome IV — stereotypical incapacitating episodes weeks apartFunctional Abdominal Pain — NOSRome IV — the residual category, reached after the other threeNonretentive Faecal IncontinenceRome IV — soiling without retention, where laxatives make it worseFunctional DyspepsiaRome IV — with PDS and EPS subtypingRumination SyndromeRome IV — effortless regurgitation without retchingCyclic Vomiting SyndromeRome IV — stereotypical episodic vomitingCannabinoid HyperemesisRome IV — CVS pattern relieved by cannabis cessationChronic Nausea & VomitingRome IV — chronic nausea and vomiting syndromeBelching DisordersRome IV — supragastric vs gastric belchingFunctional HeartburnRome IV — heartburn with normal acid exposureReflux HypersensitivityRome IV — normal acid exposure, positive symptom associationFunctional Chest PainRome IV — non-cardiac, non-reflux chest painGlobusRome IV — painless lump-in-throat sensationFunctional DysphagiaRome IV — dysphagia with normal endoscopy and manometry
  1. Calculators
  2. /
  3. CLIF-C ACLF
Liver & Cirrhosis

CLIF-C ACLF

Mortality prediction in acute-on-chronic liver failure

CLIF-C OF — organ systems

Each system scores 1, 2 or 3, for a total between 6 and 18. This is the CLIF-C OF table, which is not the same as the 0–4 CLIF-SOFA table.

Liver: 1 below 6, 2 from 6 to under 12, 3 at 12 and above.

Kidney: 1 below 2.0, 2 from 2.0 to under 3.5, 3 at 3.5 and above. Renal replacement therapy scores 3 whatever the creatinine.

Overrides the creatinine to a kidney score of 3.

Brain: 1 for grade 0, 2 for grades I–II, 3 for grades III–IV. Note this differs from CLIF-SOFA, which scores the grade directly.

Coagulation: 1 below 2.0, 2 from 2.0 to under 2.5, 3 at 2.5 and above.

Circulation: 1 at 70 and above, 2 below 70. Vasopressor use scores 3 regardless.

Overrides the mean arterial pressure to a circulation score of 3.

Respiratory

Enter whichever ratio you have. PaO₂/FiO₂ is used in preference when both are given; with neither, the system scores 1 and the result says so.

1 above 300, 2 from above 200 to 300, 3 at 200 and below.

Used only when PaO₂/FiO₂ is blank. 1 above 357, 2 from above 214 to 357, 3 at 214 and below.

Age and white cell count

Enters the equation directly, weighted 0.04 per year — a 20-year age difference moves the score by 8 points.

Entered as ×10⁹/L, which is the same number as ×10³/µL. Enters as a natural logarithm, so it matters most at the low end.

For patients who already have ACLF — establish that first, then use this for prognosis. The score is most informative when repeated: in the derivation cohort it predicted 28-day mortality better at 48 hours and at 3–7 days than at diagnosis, so a single value on admission is the weakest way to use it.

When to use
Use it once acute-on-chronic liver failure has been established, to quantify short-term mortality risk and to track whether a patient is improving or deteriorating over the first days of treatment. It is a prognostic instrument for a population already defined as having ACLF; it does not diagnose ACLF, and it does not assign an ACLF grade. Establish the diagnosis and grade first using the CANONIC organ-failure definitions, then apply this score to the patients who meet them.
Why use it
Because the scores reached for by habit in cirrhosis were built for a different question. MELD was derived to predict survival after transjugular intrahepatic portosystemic shunt and now allocates elective transplants; Child-Pugh grades chronic severity. Neither was designed for a patient with multiple acute organ failures on a cirrhotic background, and both underestimate risk in that setting. CLIF-C ACLF was derived specifically in ACLF patients and significantly outperformed all three, reducing prediction error by 19–28% at 28, 90, 180 and 365 days in both the derivation and external validation cohorts. It also adds two variables the older scores ignore entirely — age, and the white cell count as a marker of the systemic inflammation that drives this syndrome.
Formula, evidence and interpretation

About the CLIF-C ACLF Score (CLIF Consortium Acute-on-Chronic Liver Failure Score)

Three inputs drive it: the CLIF-C OF organ failure score, age, and white cell count, combined as CLIF-C ACLF = 10 × (0.33 × CLIF-C OF + 0.04 × age + 0.63 × ln(white cell count ×10⁹/L) − 2). It applies only to patients who already have acute-on-chronic liver failure, and it predicts mortality more accurately than MELD, MELD-Na or Child-Pugh, cutting prediction error by 19–28% at every time point tested. A score of 70 or above at intensive care admission carried over 80% 28-day mortality, which is the threshold at which futility of organ support is reasonably discussed when transplantation is not available. The score is most useful repeated — it predicted 28-day mortality better at 48 hours and at 3–7 days than at diagnosis.

On this page

  • Formula
  • Interpreting the result
  • Inputs
  • What it returns
  • How it is calculated
  • Facts & figures
  • Evidence
  • How it compares
  • Pearls & pitfalls
  • Critical actions
  • Why it exists
  • About the creator
  • Limitations
  • If you are the patient
  • FAQ
  • Related calculators
  • References

Formula

CLIF-C ACLF = 10 × (0.33 × CLIF-C OF + 0.04 × age [years] + 0.63 × ln(white cell count [×10⁹/L]) − 2)
CLIF-C OF
The CLIF Consortium Organ Failure score: six systems (liver, kidney, brain, coagulation, circulation, respiration), each scored 1, 2 or 3, summed to a total between 6 and 18.
age
Age in years, entered directly and weighted 0.04 per year.
ln(white cell count)
Natural logarithm of the white cell count expressed as ×10⁹/L. A count of 10 contributes 0.63 × ln(10) = 1.45 to the bracket, or 14.5 points to the final score.
  • The CLIF-C OF table scores each organ 1–3. This is NOT the CLIF-SOFA table, which scores each organ 0–4, and the thresholds are not the same table collapsed — the kidney bands in particular split at 2.0 and 3.5 mg/dL here.
  • Renal replacement therapy forces the kidney subscore to 3, and vasopressor use forces the circulation subscore to 3, regardless of the underlying creatinine or blood pressure.
  • Encephalopathy grades I and II are banded together at a brain subscore of 2. CLIF-SOFA scores the grade directly, so the same patient produces different subscores in the two systems.
  • The white cell term is logarithmic, not linear, so it matters far more at the low end of the range than the high end.
  • The score has no upper cap. Values above 70 are meaningful rather than an indication of a data-entry error.

Interpreting the result

Read the score as a position within an ACLF population, never as an absolute risk for a general cirrhotic patient — everyone this score applies to is seriously ill. The number that carries the most weight in practice is 70: in an intensive care validation cohort, over 80% of patients scoring 70 or above on admission were dead within 28 days, and that threshold has been proposed as the point at which the futility of continued organ support is reasonably discussed where transplantation is not feasible. Treat it as a prompt for that conversation rather than a decision rule, particularly as the score does not distinguish a reversible precipitant from an irreversible one. The more important habit is serial measurement: the derivation study found the score computed at 48 hours and at 3–7 days predicted 28-day mortality significantly better than the score at diagnosis, so a single admission value is the least informative way to use it.

ScoreBandWhat it meansAction
< 45Lower risk within ACLFLower mortality relative to other ACLF patients, which is not the same as low mortality — every patient in scope has organ failure on a cirrhotic backgroundTreat the precipitant, support failing organs, recompute at 48 hours
45–64Intermediate riskSubstantial short-term mortality within an ACLF populationAssess transplant candidacy early; recompute at 48 hours and again at 3–7 days, since the serial score discriminates better
65–69High riskHigh short-term mortality; approaching the threshold studied for futilityUrgent transplant assessment if the patient is a candidate; recompute at 48 hours before drawing conclusions
≥ 70Very high riskOver 80% 28-day mortality among patients at this score on intensive care admissionEmergency transplant assessment if a candidate; where transplantation is not feasible, discuss goals and the ceiling of organ support

What the CLIF-C ACLF needs (8 inputs)

Total bilirubin (liver)
Scores 1 below 6 mg/dL, 2 from 6 to under 12, and 3 at 12 and above. Note the CLIF-C OF liver bands are wider than the CLIF-SOFA ones.
Serum creatinine (kidney)
Scores 1 below 2.0 mg/dL, 2 from 2.0 to under 3.5, and 3 at 3.5 and above. Renal replacement therapy scores 3 whatever the creatinine reads.
Hepatic encephalopathy grade (brain)
Scores 1 for grade 0, 2 for grades I–II banded together, and 3 for grades III–IV. This banding is a real difference from CLIF-SOFA, which scores the West Haven grade directly.
INR (coagulation)
Scores 1 below 2.0, 2 from 2.0 to under 2.5, and 3 at 2.5 and above.
Mean arterial pressure (circulation)
Scores 1 at 70 mmHg and above, 2 below 70. Vasopressor requirement scores 3 regardless of the recorded pressure — a patient whose pressure is normal only because of noradrenaline has circulatory failure.
PaO₂/FiO₂ or SpO₂/FiO₂ (respiratory)
PaO₂/FiO₂ scores 1 above 300, 2 from above 200 to 300, and 3 at 200 and below. SpO₂/FiO₂ scores 1 above 357, 2 from above 214 to 357, and 3 at 214 and below. The arterial ratio is used in preference when both are available.
Age (years)
Enters the equation directly, weighted 0.04 per year. Twenty years of age difference moves the final score by exactly 8 points, which is often more than a whole organ subscore contributes.
White cell count (×10⁹/L)
Entered as ×10⁹/L, numerically the same as ×10³/µL. It enters as a natural logarithm, so it discriminates most at the low end: halving the count from 10 to 5 removes about 4.4 points, while doubling it from 20 to 40 adds the same 4.4.

Units. Bilirubin and creatinine are entered in mg/dL with a µmol/L toggle; divide µmol/L by 17.1 for bilirubin and by 88.4 for creatinine if converting by hand. The white cell count is the one to watch: it must be entered as ×10⁹/L (for example 9.5), which is numerically identical to ×10³/µL and to the 'K/µL' many US laboratories report. Entering an absolute count such as 9,500 will inflate the score by roughly 43 points.

What it returns

CLIF-C OF score
The organ failure component, 6 to 18, from six systems scored 1 to 3 each. Reported alongside the final score because it is the part that changes fastest with treatment.
CLIF-C ACLF score
A continuous value, in practice roughly 25 to 100. Higher is worse. There is no ceiling built into the formula.
Risk band
Anchored on the 70-point threshold from the intensive care validation study, above which 28-day mortality exceeded 80%.

How it is calculated

The CANONIC study established that acute-on-chronic liver failure is a distinct syndrome rather than simply advanced cirrhosis, characterised by organ failure and a high short-term mortality driven by systemic inflammation. Having defined the syndrome, the consortium needed a prognostic score for it, because the instruments in routine use had all been derived elsewhere. Jalan and colleagues developed CLIF-C ACLF in 275 patients with ACLF drawn from the 1,349-patient CANONIC cohort, and validated it externally. They first simplified the organ-failure assessment into the CLIF-C OF score, scoring each of six systems 1 to 3, then found that adding two variables to it improved discrimination substantially: age, which reflects the reserve available for recovery, and the white cell count, which stands in for the systemic inflammatory response that drives the syndrome's progression. The logarithmic treatment of the white cell count reflects that the prognostic information is concentrated at lower counts rather than scaling linearly with leucocytosis.

Facts & figures

The CLIF-C OF table — each system scores 1, 2 or 3
SystemScore 1Score 2Score 3
Liver — bilirubin (mg/dL)< 66 to < 12≥ 12
Kidney — creatinine (mg/dL)< 2.02.0 to < 3.5≥ 3.5 or renal replacement
Brain — West Haven gradeGrade 0Grade I–IIGrade III–IV
Coagulation — INR< 2.02.0 to < 2.5≥ 2.5
Circulation — MAP (mmHg)≥ 70< 70Vasopressors
Respiratory — PaO₂/FiO₂> 300> 200 to 300≤ 200
Respiratory — SpO₂/FiO₂> 357> 214 to 357≤ 214

Total ranges from 6 to 18. This is the CLIF-C OF table and it is not interchangeable with the 0–4 CLIF-SOFA table — the same patient produces different subscores in each, most obviously for encephalopathy, where CLIF-SOFA scores the grade directly and CLIF-C OF bands grades I and II together.

What each input contributes to the final score
ChangeEffect on CLIF-C ACLF
One point of CLIF-C OF+3.3 points
One year of age+0.4 points
Twenty years of age+8.0 points
White cell count 5 → 10 ×10⁹/L+4.4 points
White cell count 10 → 20 ×10⁹/L+4.4 points
A full organ system failing (1 → 3)+6.6 points

Useful for sanity-checking a result. The age term surprises people: a 70-year-old and a 50-year-old with identical organ failures and white cell counts differ by 8 points, more than a whole organ system moving from normal to failing.

Evidence

Derivation — Jalan et al., CANONIC

2014 · n = 275

275 patients with acute-on-chronic liver failure drawn from the 1,349-patient CANONIC study of the EASL-CLIF Consortium. The CLIF-C OF score was first derived as a simplified six-system organ failure score, then age and white cell count were added to produce the CLIF-C ACLF score.

Significantly higher predictive accuracy than MELD, MELD-Na and Child-Pugh, reducing the corresponding prediction error rates by 19–28% at 28, 90, 180 and 365 days after ACLF diagnosis, in both the CANONIC and the external validation cohorts. The score computed at 48 hours, 3–7 days and 8–15 days after diagnosis predicted 28-day mortality significantly better than the score at diagnosis.

Futility threshold in intensive care — Engelmann et al.

2018

Validation study examining whether the CLIF-C ACLF score can define a threshold for futility of intensive care support in patients with acute-on-chronic liver failure.

Over 80% of patients with a CLIF-C ACLF score of 70 or above at intensive care admission died within 28 days. The authors proposed this as a threshold at which futility may reasonably be discussed where transplantation is not an option.

Independent ICU validation

2023

Cirrhotic patients with ACLF requiring intensive care, comparing the CLIF-C OF and CLIF-C ACLF scores for transplant-free survival.

For 28-day mortality, CLIF-C ACLF achieved an AUROC of 0.717 (95% CI 0.626–0.809) against 0.652 (95% CI 0.554–0.750) for CLIF-C OF alone, confirming that the age and white cell count terms add discrimination over the organ failure score by itself.

CANONIC — the study that defined the syndrome

2013 · n = 1,343

Prospective observational study of 1,343 patients admitted with acutely decompensated cirrhosis across 29 European units, which established acute-on-chronic liver failure as a distinct syndrome with its own organ failure definitions and mortality profile.

Defined the organ failure criteria and ACLF grades on which the CLIF-C family is built, and established the high short-term mortality that motivated a dedicated prognostic score.

How it compares

CLIF-C ACLF vs CLIF-SOFA

Sequential, not alternative — CLIF-SOFA (with the CANONIC definitions) establishes whether ACLF is present and its grade; CLIF-C ACLF then quantifies mortality risk in the patients who have it.

CLIF-SOFA scores each of six organ systems 0–4 and is used to identify organ failures and assign an ACLF grade. CLIF-C OF is a deliberately simplified 1–3 version of the same six systems, built as the organ-failure component of this prognostic score. The tables are not interchangeable: the thresholds differ, and encephalopathy in particular is banded I–II here but scored by grade in CLIF-SOFA. Use the first to define the syndrome, the second to prognosticate within it.

Open the CLIF-SOFA calculator →

CLIF-C ACLF vs MELD / MELD-Na

CLIF-C ACLF is the more accurate score in established ACLF, reducing prediction error by 19–28% against MELD and MELD-Na at every time point tested.

MELD was derived to predict survival after TIPS and now governs elective transplant allocation; it contains no measure of circulatory, respiratory or cerebral failure and no measure of inflammation, so it systematically underestimates risk in a patient with several organs failing at once. CLIF-C ACLF was derived in ACLF patients specifically and outperformed MELD, MELD-Na and Child-Pugh at 28, 90, 180 and 365 days. MELD retains its role in allocation; it is simply the wrong instrument for prognosis in this syndrome.

Open the MELD / MELD-Na calculator →Jalan R, Saliba F, Pavesi M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014;61(5):1038-1047.

CLIF-C ACLF vs AARC-ACLF (APASL)

They describe different patient populations because APASL and EASL-CLIF define ACLF differently — pick the one matching the definition your unit uses.

The APASL definition requires acute hepatic insult with jaundice and coagulopathy in chronic liver disease and excludes patients with prior decompensation, so it centres on liver failure. The EASL-CLIF definition behind CLIF-C ACLF is built on extrahepatic organ failure and includes previously decompensated patients. AARC therefore uses liver-centred variables (bilirubin, INR, lactate, creatinine, encephalopathy) while CLIF-C ACLF weighs six organ systems plus age and inflammation. Neither is wrong; they answer the same question about different cohorts.

Open the AARC-ACLF (APASL) calculator →

CLIF-C ACLF vs Child-Pugh score

Not suitable here — Child-Pugh grades chronic disease severity and was outperformed by CLIF-C ACLF at every time point in the derivation study.

Child-Pugh includes albumin, whose 20-day half-life makes it nearly uninformative over the days across which ACLF evolves, and it captures no renal, circulatory or respiratory failure at all. It remains useful for staging chronic liver disease and for drug-dosing decisions, but it is not a prognostic instrument for a patient with multi-organ failure.

Open the Child-Pugh score calculator →

Pearls & pitfalls

  • CLIF-C OF is not CLIF-SOFA. One scores each organ 1–3, the other 0–4, and they are not the same table collapsed. Using CLIF-SOFA subscores in this formula produces a meaningless number.
  • Encephalopathy grades I and II are banded together at a brain subscore of 2 here, whereas CLIF-SOFA scores the West Haven grade directly. This is the single easiest subscore to carry across incorrectly.
  • The white cell count goes in as ×10⁹/L, which is the same number as ×10³/µL. Entering an absolute count such as 9,500 instead of 9.5 will inflate the score by about 43 points.
  • Vasopressors force circulation to 3 and renal replacement forces kidney to 3. A normal-looking blood pressure on noradrenaline is circulatory failure, not a normal circulation.
  • This score does not diagnose ACLF and does not assign a grade. Establish both first using the CANONIC definitions; applying this score to a decompensated cirrhotic without organ failure is outside what it was derived for.
  • A single value on admission is the weakest way to use it. The derivation study showed the score at 48 hours and at 3–7 days predicted 28-day mortality significantly better than the score at diagnosis.
  • The 70-point futility threshold comes from an intensive care cohort at the point of ICU admission. It is a prompt for a conversation, not a rule, and it does not distinguish a treatable precipitant from an untreatable one.
  • Age carries more weight than clinicians expect — 8 points across a 20-year difference, more than a whole organ system moving from normal to failing.

Critical actions

  • Confirm ACLF is actually present, using the CANONIC organ-failure definitions, before applying this score at all.
  • Identify and treat the precipitant immediately — bacterial infection above all, then alcohol-related hepatitis, variceal bleeding and drug injury. The score describes prognosis; it does not tell you what will change it.
  • Recompute at 48 hours and again at 3–7 days, and act on the trajectory rather than the admission value.
  • Assess transplant candidacy early rather than after further organs fail, since the window narrows as the score rises.
  • At a score of 70 or above without a transplant option, open an explicit conversation with the family and the wider team about goals and the ceiling of organ support.
  • Recheck the white cell count entry if the score looks implausible — a unit error there is the commonest cause of a wildly wrong result.

Why this score exists

The score exists because the CANONIC investigators had just demonstrated that acute-on-chronic liver failure was a distinct syndrome, and then found themselves without an instrument to prognosticate in it. Every score being applied to these patients had been derived somewhere else for something else — MELD for post-TIPS survival, Child-Pugh for shunt surgery risk — and all of them underestimated mortality in a patient with several organs failing at once. The two additions beyond organ failure are the interesting editorial choice: age, and the white cell count. Neither appears in MELD or Child-Pugh, and the white cell count in particular reflects the consortium's position that ACLF is driven by systemic inflammation rather than simply by the failure of the liver. Its logarithmic form encodes that the prognostic signal sits at the lower end of the range rather than scaling with the height of a leucocytosis.

About the creator

  • Rajiv Jalan

    First author, 2014 derivation study; Institute for Liver and Digestive Health, University College London

    Led the development and validation of the CLIF-C OF and CLIF-C ACLF scores within the EASL-CLIF Consortium.

  • Faouzi Saliba

    Co-author of the 2014 derivation study.

  • Marco Pavesi

    Data Management Centre, EASL-CLIF Consortium

    Statistical lead for the CANONIC study and the CLIF-C score development.

Limitations

  • Applies only to patients who already meet a definition of ACLF. It neither diagnoses the syndrome nor assigns a grade, and it has not been validated in decompensated cirrhosis without organ failure.
  • Derived and validated predominantly in European cohorts under the EASL-CLIF definition, which differs from the APASL definition used across much of Asia — the two select different patients, so performance does not transfer automatically.
  • The white cell count is a crude proxy for systemic inflammation and is confounded by corticosteroids, active infection, gastrointestinal bleeding and recent transfusion.
  • Prognostic only. It identifies who is likely to die but says nothing about which intervention would change that, and it does not separate reversible precipitants from irreversible ones.
  • The 70-point futility threshold derives from a specific intensive care population measured at ICU admission. Applying it at a different point in the illness, or to a patient with a treatable precipitant, is not what the study supports.
  • Discrimination is good but not excellent — AUROC around 0.72 for 28-day mortality in independent ICU validation. It should inform discussion, never settle it alone.
  • Performance depends on organ-failure data being complete; a missing oxygenation ratio defaults the respiratory system to its lowest subscore and will understate the score.

If you are the patient

Acute-on-chronic liver failure means that someone with long-standing liver disease has become suddenly and severely unwell, with several organs — not just the liver — starting to fail at once. The CLIF-C ACLF score is a number the medical team calculates to judge how serious the situation is over the coming weeks. It combines how many organs are struggling and how badly, the person's age, and a blood test that reflects how much inflammation is present. A higher number means a higher risk. The team will usually recalculate it after a couple of days, because how the number moves with treatment tells them more than the first value did — a score that falls as an infection is treated means something quite different from one that keeps climbing. If the score is very high and a liver transplant is not possible, the team may start a conversation about what treatment can realistically achieve. That conversation is guided by the number, not decided by it.

Frequently asked questions

What is the CLIF-C ACLF score?#

A prognostic score for patients with acute-on-chronic liver failure, calculated as 10 × (0.33 × CLIF-C OF score + 0.04 × age + 0.63 × ln(white cell count ×10⁹/L) − 2). It predicts short-term mortality more accurately than MELD, MELD-Na or Child-Pugh in this population.

Is CLIF-C OF the same as CLIF-SOFA?#

No, and confusing them is the commonest error with this score. CLIF-SOFA scores each of six organ systems 0–4; CLIF-C OF scores the same six systems 1–3 with different thresholds, giving a total of 6 to 18. Encephalopathy is the clearest divergence — CLIF-C OF bands grades I and II together, while CLIF-SOFA scores the grade directly.

What CLIF-C ACLF score indicates futility?#

A score of 70 or above at intensive care admission was associated with over 80% 28-day mortality, and has been proposed as a threshold at which futility of continued organ support may reasonably be discussed when transplantation is not feasible. It is a prompt for that discussion rather than a decision rule, and it does not account for a reversible precipitant.

How often should the score be repeated?#

At least at 48 hours and again at 3–7 days. The derivation study found the score computed at those points predicted 28-day mortality significantly better than the score at diagnosis, which makes the trajectory more informative than any single value.

What units does the white cell count use?#

×10⁹/L, for example 9.5 — the same number as ×10³/µL or K/µL. Entering an absolute count such as 9,500 will add roughly 43 points to the score, so it is worth a second look whenever a result seems implausibly high.

Can I use CLIF-C ACLF instead of MELD for transplant listing?#

No. MELD and its variants govern elective transplant allocation and that role is unchanged. CLIF-C ACLF is a prognostic score for patients who already have ACLF, where it is the more accurate predictor of mortality, but it is not an allocation instrument.

Does this score diagnose acute-on-chronic liver failure?#

No. Establish the diagnosis and the ACLF grade first using the CANONIC organ-failure definitions, then apply this score to quantify risk in patients who meet them.

Why does age carry so much weight?#

Age is weighted 0.04 per year, so twenty years adds exactly 8 points to the final score — more than a whole organ system moving from normal to failing, which adds 6.6. It reflects the physiological reserve available for recovery, something MELD and Child-Pugh omit entirely.

Related calculators

  • CLIF-SOFA — Organ failure scoring in cirrhosis
  • AARC-ACLF — Acute-on-chronic liver failure grade
  • MELD-Na — Assesses the severity of chronic liver disease
  • Child-Pugh Score — Assesses the prognosis of chronic liver disease, mainly cirrhosis
  • West Haven Criteria — Hepatic encephalopathy grading
  • King's College Criteria — Transplant criteria in acute liver failure
  • Maddrey's DF — Alcoholic hepatitis severity

References

Original / primary reference

  1. Jalan R, Saliba F, Pavesi M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014;61(5):1038-1047.
  2. Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426-1437.

Validation and thresholds

  1. Engelmann C, Thomsen KL, Zakeri N, et al. Validation of CLIF-C ACLF score to define a threshold for futility of intensive care support for patients with acute-on-chronic liver failure. Crit Care. 2018;22(1):254.

Guidelines

  1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460.
  2. Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL): an update. Hepatol Int. 2019;13(4):353-390.

Last updated August 1, 2026. Clinical knowledge base written and curated by GastroAGI Team from primary medical literature.

Written from primary literature and not yet independently clinically reviewed.

For use by qualified healthcare professionals. This calculator supports clinical judgement and does not replace it.